Welcome to #TenTweetNephJC
✳️ 10 tweets #NephJC catch-up ✳️
Here’s a recap of our 25th Oct #NephJC discussion on ‘Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus’ - better late than never!
Check out the paper at pubmed.ncbi.nlm.nih.gov
✳️ 10 tweets #NephJC catch-up ✳️
Here’s a recap of our 25th Oct #NephJC discussion on ‘Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus’ - better late than never!
Check out the paper at pubmed.ncbi.nlm.nih.gov
2/10 What did I miss?
This #NephJC discussion led by @ParamMD and @raad_chowdhury took a deep dive into the engineering of CAR-T cells targeting CD19 for immunotherapy in patients with lupus nephritis and examined safety, efficacy, and B-cell depletion.
This #NephJC discussion led by @ParamMD and @raad_chowdhury took a deep dive into the engineering of CAR-T cells targeting CD19 for immunotherapy in patients with lupus nephritis and examined safety, efficacy, and B-cell depletion.
3/10
1 tweet methods
✅ Open-label, phase I
✅ 5 patients with active, refractory lupus nephritis
✅ Intervention = CD19-directed chimeric antigen receptor (CAR) T cells
✅ Leukapheresis ➡️ CAR T cells produced ➡️ chemo given to deplete own T-cells ➡️ CAR T infusion performed
1 tweet methods
✅ Open-label, phase I
✅ 5 patients with active, refractory lupus nephritis
✅ Intervention = CD19-directed chimeric antigen receptor (CAR) T cells
✅ Leukapheresis ➡️ CAR T cells produced ➡️ chemo given to deplete own T-cells ➡️ CAR T infusion performed
4/10
1 tweet results
All patients showed:
🔹Reduction in SLE disease activity (SLEDAI-2K scores)
🔹Decreased dsDNA Abs, decreased proteinuria, and restoration of complement levels
🔹 Depletion of memory B cells, activated memory B cells, and plasmablasts
1 tweet results
All patients showed:
🔹Reduction in SLE disease activity (SLEDAI-2K scores)
🔹Decreased dsDNA Abs, decreased proteinuria, and restoration of complement levels
🔹 Depletion of memory B cells, activated memory B cells, and plasmablasts
5/10
A figure paints 1000 words
CAR T cell therapy dramatically reduced lupus disease activity in all patients.
A figure paints 1000 words
CAR T cell therapy dramatically reduced lupus disease activity in all patients.
6/10
Give me something clever to say
“ Is the horse before the CAR T in SLE?”
(clever title of our summary nephjc.com)
Give me something clever to say
“ Is the horse before the CAR T in SLE?”
(clever title of our summary nephjc.com)
7/10
Chat consensus?
1️⃣ Results are exciting, but more data/larger studies are needed
2️⃣ CAR T technology could potentially be used for other immune-mediated kidney diseases, such as membranous nephropathy or IgA nephropathy
Chat consensus?
1️⃣ Results are exciting, but more data/larger studies are needed
2️⃣ CAR T technology could potentially be used for other immune-mediated kidney diseases, such as membranous nephropathy or IgA nephropathy
8/10
Quote of the fortnight!
“Is there a sweeter phrase in SLE Nephritis than “drug-free remission?” @kidney_boy
Quote of the fortnight!
“Is there a sweeter phrase in SLE Nephritis than “drug-free remission?” @kidney_boy
9/10
I want more info
✅ Check out the summary from @ParamMD
nephjc.com
✅ @Nephro_Sparks gave us an excellent tweetorial, check it out here:
✅ And this lovely VA by @thana_susan
I want more info
✅ Check out the summary from @ParamMD
nephjc.com
✅ @Nephro_Sparks gave us an excellent tweetorial, check it out here:
✅ And this lovely VA by @thana_susan
10/10
Final thoughts
✳️ CD19 CAR T cell therapy is well-tolerated and a promising future therapy for lupus nephritis. All patients in the trial didn’t respond to prior treatments, so this could be an option for patients refractory to therapy.
Tweetorial by @Tiff_Caza
Final thoughts
✳️ CD19 CAR T cell therapy is well-tolerated and a promising future therapy for lupus nephritis. All patients in the trial didn’t respond to prior treatments, so this could be an option for patients refractory to therapy.
Tweetorial by @Tiff_Caza
Loading suggestions...